PROSTATE ADENOCARCINOMA

This study tested a combination of two drugs, talazoparib and temozolomide, in 16 men with advanced prostate cancer that had spread and stopped responding to hormone therapy. The goal was to find the safest dose and see if the treatment could shrink tumors. The study was complete…

This study tested a new type of radiation therapy for prostate cancer using tiny seeds that emit alpha radiation. The goal was to see if it is safe and possible to place these seeds inside the tumor before surgery. Only one person took part, and the focus was on whether the proce…

This study tested a drug called niraparib in 11 men with advanced prostate cancer that was growing despite hormone therapy. All participants had previously received platinum chemotherapy. The goal was to see if niraparib could keep the cancer from progressing for at least 6 month…

This study tested a shorter course of radiation (hypofractionation) in 52 men who had prostate cancer with high-risk features after their prostate was removed. The goal was to see if giving higher daily doses over fewer days could prevent the cancer from coming back. The approach…

This study followed 354 men with prostate cancer who chose to freeze half of their prostate gland (hemi-gland cryoablation) to destroy tumors. Researchers tracked how well the treatment controlled cancer and its impact on urinary function. The goal was to see if using advanced MR…

This pilot study tested a new way to treat low-risk prostate cancer using MRI-guided laser ablation. Seven men with early-stage prostate cancer received the treatment to see if it was safe and could successfully target and destroy tumors. The goal was to control the disease with …

This study looked at adding a drug called niraparib to standard radiation and hormone therapy for men with high-risk prostate cancer. The goal was to see if the combination could lower the chance of the cancer growing or coming back. Twenty-two men took part, and the researchers …

This study tested a new combination treatment for men with prostate cancer that stopped responding to standard hormone therapy. The treatment uses testosterone (given as shots) and a drug called olaparib to damage cancer cells' DNA, making it harder for them to survive. 36 men to…

This study tested a new type of PET/CT scan using a radioactive tracer called copper Cu 64 PSMA I&T to see if it can accurately find prostate cancer that has come back after initial treatment. 235 men with rising PSA levels after surgery or radiation took part. The goal was to se…

This study tested whether a shorter course of higher-dose radiation (hypofractionated) is better than the usual longer course of radiation for men who had prostate cancer surgery. About 296 men took part. The main goal was to see how each approach affects urinary and bowel qualit…

This early-stage trial tested a new dye called Illuminare-1 that makes nerves glow during prostate cancer surgery. The goal was to help surgeons avoid damaging nerves, which can cause side effects like incontinence and erectile dysfunction. The study involved 41 men and focused o…

This early-stage study tested a precise, high-dose radiation technique called stereotactic body radiotherapy (SBRT) in 42 people with breast, lung, or prostate cancer that had spread to several places in the body. The main goal was to find the safest dose and check for side effec…

This study looked at whether a diet and exercise program could help prevent or reduce metabolic side effects (like weight gain, insulin resistance, and unhealthy cholesterol levels) caused by hormone therapy (ADT) in men with prostate cancer. Twenty men undergoing radiation and h…

This study looked at whether giving prostate cancer survivors on hormone therapy more detailed survivorship care plans helps them get better heart health follow-up. About 550 men who had radiation and hormone therapy took part. Researchers checked if patients saw their primary ca…